571189-49-6CN1CCN(c2ccc(N)nc2)CC1QDMPMBFLXOWHRY-UHFFFAOYSA-N571189-49-6DTXSID80624889CHEMBL4535536Light yellow to Brown powder to crystal.
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H301 (33.3%): Toxic if swallowed [Danger Acute toxicity, oral]
P203, P260, P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P301+P317, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P316, P317, P318, P319, P321, P330, P332+P317, P337+P317, P362+P364, P363, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 6 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
개요5-(4-Methylpiperazin-1-yl)pyridin-2-amine is a pharmaceutical intermediate compound that can be used to prepare trilaciclib. Trilaciclib is the first intravenous CDK4/6 inhibitor approved by the FDA for reducing the risk of bone marrow suppression (i.e. decreased red blood cells, white blood cells, and platelets) in adult patients with small cell lung cancer (SCLC) caused by specific chemotherapy drugs.
용도5-(4-Methylpiperazin-1-yl)pyridin-2-amine can be used for chemical mechanical planarization for tungsten-containing substrates.